Kunal Jobanputra MD, DM(@KNJobanputra) 's Twitter Profileg
Kunal Jobanputra MD, DM

@KNJobanputra

Medical Oncologist | DM MedOnc @tatamemorial | MD Med (KEM Mumbai) | Cycling | Nature, history & culture

ID:985857518193823746

calendar_today16-04-2018 12:28:43

1,2K Tweets

710 Followers

370 Following

Kunal Jobanputra MD, DM(@KNJobanputra) 's Twitter Profile Photo

What is the average lag between prescribing an antibiotic in an inpatient and actual administration of antibiotic in your setup?

account_circle
Kunal Jobanputra MD, DM(@KNJobanputra) 's Twitter Profile Photo

Sad to see patients with autoimmune diseases developing life-threatening Methotrexate toxicity due to overdosage (daily instead of weekly). No one takes VitD daily. What’s different with Mtx?

account_circle
Sarju Ganatra, MD, FACC(@SarjuGanatraMD) 's Twitter Profile Photo

Even from 93 million miles away, solar storms grace us with the , reminding us of our deep connection to this vast universe.

Let's honor that bond by taking care of our planet with practices & mindfulness to respect the cosmos

Even from 93 million miles away, solar storms grace us with the #NorthernLights #aurora, reminding us of our deep connection to this vast universe. Let's honor that bond by taking care of our planet with #sustainableLiving practices & mindfulness to respect the cosmos
account_circle
JAMA Oncology(@JAMAOnc) 's Twitter Profile Photo

The 10-year interval between colonoscopy screenings for colorectal cancer (CRC) could be extended to 15 years in patients with no family history of CRC and negative findings on their first colonoscopy, finds matched cohort study. ja.ma/44rKeUj

The 10-year interval between colonoscopy screenings for colorectal cancer (CRC) could be extended to 15 years in patients with no family history of CRC and negative findings on their first colonoscopy, finds matched cohort study. ja.ma/44rKeUj
account_circle
OncoAlert(@OncoAlert) 's Twitter Profile Photo

Just Out by OUR AMAZING OncoAlert 🚨Faculty
Emre Yekedüz , Yüksel Ürün 🇹🇷and team Sati Coskun Yazgan, Erman Akkus

Thromboembolic Risk in Patients Treated with PARP Inhibitors

Meta-analysis of phase II and phase III clinical trials examining the use of poly

Just Out by OUR AMAZING @OncoAlert 🚨Faculty @yekeduz_emre , @DrYukselUrun 🇹🇷and team Sati Coskun Yazgan, @Erman_Akkus Thromboembolic Risk in #ProstateCancer Patients Treated with PARP Inhibitors Meta-analysis of phase II and phase III clinical trials examining the use of poly
account_circle